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The acute effects of ACE inhibition on neurohormonal activation are complex.
Sympathetic tone decreases as a direct result of angiotensin II reduction;
however, an increase in bradykinin may stimulate sympathetic tone. Conse-
quently, divergent coronary and systemic hemodynamic effects may ensue.
As these acute ACE inhibitor effects are incompletely identified in humans,
49 pts with significant (>70%) CAD received enalaprilat. perindoprilat or cap-
topril intravenously, which resulted in immediate 1:0:5') 73% ACE inhibition
and a 52% reduction in arterial angiotensin II. Twenty-two patients received
placebo. During a 15-minute study protocol. placebo induced no changes. In
the treated group, arterial norepinephrine (NE) increased at 5 and 15 minutes
by 11 % and 12%, respectively, and arterial epinephrine (E) by 11 % and 14%,
respectively. Heart rate did not change, but contractility (VMAX) increased by
13% and 4%, respectively. Mean arterial pressure (MAP) decreased by 2%
and 5% and systemic vascular resistance (SVR) decreased by 4% and 7%,
respectively. Despite the reduction in coronary perfusion pressure, coronary
blood flow (CBFj increased by 8% at 5 minutes, while coronary vascular re-
sistance ICVR) decreased by 10% and 11 %, respectively, at 5 and 15 min-
utes. ArteriaI6-keto-F2a, the prostacyclin metabolite, was 52% higher com-
pared to placebo, but increased late, at 15 minutes. Other prostaglandins
and cardiac neurohormonal balances remained unaltered. Thus, in contrast
to the well-known modulation of sympathetic activity by chronic converting
enzyme inhibition, acute ACE inhibition results in an immediate increase in
cirCUlating catecholamines and improves myocardial contractility and coro-
nary flow. The effect on sympathetic tone and contractility cannot be ex-
plained by changes in circulating angiotensin II and prostaglandins or cardiac
renin-angiotensin, which suggests a bradykinin-related effect.
Ad F.M. van den Heuvel, Martin van der Ent Willem J. Remme Sticares Foundation,
Rotterdam, The Netherlands
pressor vasoactivity correctly predicted the presence of coronary disease in
76% of the subjects using a predetermined criterion. Mean flow-mediated di-
ameterincreased 9.11 ± 6.01 % and 6.58 ± 7.50% in the normal and coronary
disease subjects, respectively (P = NS), Responses to sublingual nitroglyc-
erin were the same in the two groups. Using multiple stepwise regression
analysis, cold-pressor vasoactivity was found to be dependent upon smoking
status (p = 0.0002) and the presence of coronary disease (p = 0.04). In the
32 non-smokers undergoing assessment, the presence of coronary disease
was the only significant determinant of cold pressor vasoactivity (p ~ 0.02).
Flow-mediated vasoactivity was found to be dependent on smoking status
(p = 0.005) and baseline brachial artery diameter (p = 0.02), Flow-mediated
vasoactivity correlated with total cholesterol by univariate but not multivari-
ate analysis. The associations of brachial artery vasoactivity with cardiac risk
factors and coronary disease appear to be stimulus dependent. Cold pressor
vasoactivity correlates more closely with the presence of coronary disease
than does flow-mediated vasoactiVity, These findings suggest that abnormal
cold pressor vasoactivity is a generalized vascular marker for atherosclero-
sis, but that flow-mediated vasoactivity correlates with the presence of risk
factors.
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Brachial Artery Vasoactivity: Cold Pressor but not
Flow-Mediated Responses Correlate with the
Presence of Coronary Artery Disease
Robert A. Vogel, Mary C. Corretti, Gary D. Plotnick. University of Mary/and School of
Medicine, Baltimore, MD
11:15
Cigarette Smoking Inhibits Basal but not Stimulated
Release of Nitric Oxide from the Forearm Vasculature
Gary E. McVeigh. Lisa LeMay. Dennis J. Morgan. Jay N. Cohn. University of
Minnesota, Minneapolis. MN
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Risk Factor Modification Improves Flow-Mediated
Brachial Artery Vasoactivity but not Cold Pressor
Vasoactivity in Men with Coronary Artery Disease
Mary C. Corretti, Gary D. Plotnick, Michael Miller, Robert A. Vogel. University of
Maryland Hospital, 8a/~'more, MD
To evaluate the effects of cigarette smoking on endothelial function, we ex-
amined forearm vascular responses to the intra-brachial infusion of metha-
choline (MCj, NG-monomethyl-L-arginine (L-NMMA) and sodium nitroprus-
side (SN) in 36 smokers (S) and 11 non-smoking (NS) control subjects. Val-
ues are presented as means ± standard deviation. The mean age of S (42
± 7 years) was similar to NS (43 ± 11 years). Blood glucose, total and HDL-
cholesterol and serum fibrinogen concentrations were not different between
groups. S had elevated carboxyhemoglobin levels compared with NS (5.1 ±
2.5% vs, 1.1 ± 0.3%, P < 0.001). The incremental infusions of MC increased
forearm blood flow (FBF) (mill 00 ml/min) from 3.6 ± 1.2 to 12.7 ± 8.9 in S
and from 3.1 ± 0.8 to 14.7 ± 7.5 in NS (p = NS). SN increased FBF (mill 00
mllmin) from 3.7 ± 1.4 to 9.0 ± 4.7 in S and from 2.8 ± 0.3 to 8.4 ± 47 in NS
(p = NS). L-NMMA reduced FBF (m11100 mllmin) more (p = 0.03) in NS (3.9
± 0.5 to 2.2 ± 0.7) than in S (4.1 ± 1.5 to 3.3 ± 1.2) but did not attenuate the
dose response curves to MC infusion in either group.
Conclusion: Chronic cigarette smoking appears to impair basal but not
stimulated release of endothelium-derived nitric oxide from the forearm vas-
culature.
'p <0.01
FM vasoactivity normalized with risk factor modification and was similar to
our controls 11.5 ± 7.0%. CP response remained abnormal despite chronic
RFM. This suggests that FM vasoactivity is dependent on risk factor status,
but CP vasoactivity may be dependent on the presence of CAD.
Coronary risk factors are associated with impaired endothelium-mediated va-
soactivity in the peripheral and coronary circulation. To determine the effect
of risk factor modification (RFM) on brachial artery vasoactivity, we studied 23
men with coronary artery disease (CAD). Using 7.5 MHz ultrasound, brachial
artery diameter changes (%tl. Diam) in response to flow mediated (FM) and
cold pressor {CP} stimuli were measured in 13 men 1 week after the initial
presentation of ischemic heart disease and in another 10 men 1 year after
aggressive risk factor modification, (smoking cessation, lipid lowering).
Chronically managed patients had significantly lower total cholesterol and
smoking frequency.
Flow-mediated brachial artery vasoactivity is abnormal in patients with coro-
nary artery disease and cardiac risk factors. Cold pressor coronary artery va-
soactivity is abnormal in patients with coronary disease, but brachial artery
responses have not been studied. The purpose of this study was to assess
whether cold pressor and flow-mediated brachial artery vasoactivity corre-
late independently with the presence of coronary artery disease. We stud-
ied 50 men (27 clinically normal, 23 angiographically proven coronary artery
disease) ranging from 23 to 59 years old. Using 7.5 MHz ultrasound, we
measured brachial artery diameter and Doppler flow velocity at baseline,
during contralateral ice water hand immersion (cold pressor), following five
minutes of ipsilateral blood pressure cuff occlusion (flow-mediated) and fol-
lowing nitroglycerin administration. During cold pressor stimulation, mean
brachial artery diameter increased 0.36 ± 2.93% in the normal subjects but
decreased 2,38 ± 3.32% in the coronary disease subjects (p = 0.006). Cold
1787-21 Addition of ACE Inhibitors to Beta Blockers or
Calcium Channel Blockers Improves Mortality in
Patients with CAD
Rahul Chaturvedi, David Zurakowski, Saumya Sharma, GVR.K. Sharma. Dept. of
Medicine, Brockton-WestRoxburyVA.M.C., Harvard Medical School, 80ston, MA
Patients (n = 3676) with the diagnosis (Dx) of CAD discharged from our insti-
tution from 1/88 and 1/93 were followed for a mean duration of 33.3 months.
Using multiple logistic regression, with all cause mortality as the end point,
combinations of therapy (Rx) with either ACE inhibitors (A) or beta blockers
(B) or calcium channel blockers IC) were compared to Rx with C alone (n =
378). Age and the Dx of CHF, MI, COPD, DM, PVD, hypercholesterolemia,
CABG and PTCA were entered into the model. Results:
